List of Onivyde drug patents

Onivyde is owned by Ipsen Inc.

Onivyde contains Irinotecan Hydrochloride.

Onivyde has a total of 17 drug patents out of which 0 drug patents have expired.

Onivyde was authorised for market use on 22 October, 2015.

Onivyde is available in injectable, liposomal;intravenous dosage forms.

Onivyde can be used as treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, treatment of pancreatic cancer, treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient not homozygous for the ugt1a1*28 allele; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele, treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.

The generics of Onivyde are possible to be released after 15 October, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9782349 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US10722508 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US9724303 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US8992970 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US8329213 IPSEN INC Liposomes useful for drug delivery
Jan, 2027

(3 years from now)

US8147867 IPSEN INC Liposomes useful for drug delivery
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730891 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US8703181 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US11369597 IPSEN INC Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(10 years from now)

US9717724 IPSEN INC Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(10 years from now)

US9492442 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(10 years from now)

US9364473 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(10 years from now)

US9339497 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(10 years from now)

US9452162 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(10 years from now)

US10980795 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(10 years from now)

US10456360 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(13 years from now)

US10993914 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 22, 2022

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient not homozygous for the ugt1a1*28 allele; Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in